Last updated Saturday, 28 March 2009


Friday, 13 October 2006

14:00 – 18:00 Registration/Poster Set-up
18:00 – 21:00 Opening Reception followed by Dinner
Saturday, 14 October 2006
07:00 Registration opens
07:30 Breakfast
08:30 Opening Remarks
  Oral Session 1: Metabolic Assessment of Cancer Using C13 Imaging and Spectroscopy, Martin Leach, Ph.D., Chair
08:45 Magnetic Resonance Probing of Cancer Metabolism and Physiology
Hadassa Degani, Ph.D., Weizmann Institute of Science, Rehovot, Israel
09:30 Preclinical Hyperpolarized C-13 MRSI Studies of Prostate Cancer - not available
Daniel B. Vigneron, Ph.D., University of California, San Francisco, CA, USA
10:00 Break

Oral Session 2: Tumor models - MRI and the Microenvironment I, Simon Robinson, Ph.D., Chair

10:30 Imag(in)ing the Tumor Microenvironment
Robert J. Gillies, Ph.D.,
University of Arizona, Tucson, AZ, USA

Proffered Papers

10:55 Quantification of liver tumor necrotic fraction using diffusion-weighted PROPELLER MRI in the VX2 rabbit model
Jie Deng. M.Sc.,
Northwestern University, Chicago, IL, USA
11:10 The simultaneous measurement of blood flow, blood volume and Ktrans using DSC-MRI
Christopher C. Quarles, Ph.D., Vanderbilt University, Nashville, TN, USA
11:25 Multi-parametric MRI/MRSI/DTI and T2-relaxometry imaging of prostate cancer at 3T
Daniel B. Vigneron, Ph.D., University of California San Francisco, CA, USA
11:40 Tumour response to 5,6-dimethylxanthenone-4-acetic acid (DMXAA) assessed by intrinsic-susceptibility MRI
Lesley D. McPhail. B.Sc., St. George’s Hospital Medical School, London, UK     
11:55 Lunch
14:00 Poster Session 1: Clinical Assessment of Human Cancer with MRI and MRS (Odd-Numbered Posters)
15:30 Fourth Negendank Memorial Lecture, Jeffrey Evelhoch, Ph.D. Chair
To Image and Imagine: MR Molecular-Functional Imaging (MFI) of Cancer
Zaver Bhujwalla, Ph.D., Johns Hopkins University, Baltimore, MD, USA
16:15 Break
  Oral Session 3: Tumor models - MRI and the Microenvironment II, Jeff Evelhoch, Ph.D., Chair

Characterizing “Angiogenic” Contrast And Extracellular Matrix Integrity In Tumors Using MRI
Arvind P. Pathak, Ph.D., Johns Hopkins University, Baltimore, MD, USA

  Proffered Papers

Inhibition of tumor growth and angiogenesis by a novel dual EGF-R and VEGF-R inhibitor in mouse xenograft model: a DCE-MRI study
Natalie J. Serkova, Ph.D., University of Colorado Health Services, Denver, CO, USA

17:10 Characterization of prostate cancer xenografts in orthotopic and subcutaneous sites
Marie-France Penet, Ph.D., Johns Hopkins University, Baltimore, MD, USA
17:25 Prediction of human melanoma metastatic potential in mouse xenografts by MR and optical imaging
Lin Li,Ph.D., University of Pennsylvania, Philadelphia, PA, USA
18:30 Dinner
Sunday, 15 October 2006
07:30 Breakfast
  Oral Session 4: Clinical Translation of MRI, Thomas L. Chenevert, Ph.D., Chair
08:30 New Frontiers in Oncologic Imaging: Where are the Opportunities and Challenges?
Michael V. Knopp, M.D., Ohio State University, Columbus, OH, USA
08:55 Clinical Translation of MRI in Cancer
Yael Mardor, Ph.D., Sheba Medical Center, Tel-Hashomer, Israel
  Proffered Papers
09:20 Multiparametric MR studies for monitoring treatment response of head and neck cancers
Sungheon Kim, Ph.D., University of Pennsylvania, Philadelphia, PA, USA
09:35 Voxel-based analysis of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation
Wilburn E. Reddick, Ph.D., St. Jude Children’s Research Hospital, Memphis, TN, USA
09:50 Break
  Oral Session 5: Targeted Contrast Agents – Molecular Imaging, Edward J. Delikatny, Ph.D., Chair
10:10 Towards MRI Agents that Report Biological Functions
A. Dean Sherry, Ph.D., University of Texas, Dallas, TX, USA
10:35 Molecular Imaging Probes For Cancer Detection and Therapy Assessment
Anna V. Moore, Ph.D., Harvard Medical School, Charlestown, MA, USA
10:55 Targeted Contrast Agents
Dimitri Artemov, Ph.D., Johns Hopkins University, Baltimore, MD, USA
  Proffered Papers
11:25 Amide proton transfer (APT) imaging of human brain tumors: A comparison with conventional MT imaging
Jinyuan Zhou, Ph.D., Johns Hopkins University, Baltimore MD, USA
11:40 uPAR-targeted iron oxide nanoparticles for in vivo MRI of breast cancer
Xianghong Peng, Emory University School of Medicine, Atlanta, GA, USA
11:55 Lunch
13:45 Poster Session 2: Cell and Animal Models of Cancer (Even-Numbered Posters)
  Oral Session 6: Cell Imaging, Spectroscopy and Tracking, Harish Poptani, Ph.D., Chair
15:15 Imaging Tumour Responses to Therapy
Kevin Brindle, Ph.D., University of Cambridge, Cambridge, England, UK
15:40 Labeling and In-Vivo Tracking of Natural Killer Cells To Tumors - not available
Heike Daldrup-Link, University of California, San Francisco, CA, USA
16:05 Break
  Proffered Papers

Monitoring the fate of metastatic breast cancer in vivo in the mouse brain
Chris Heyn, Robarts Research Institute, London, ON, Canada   

16:35 Detecting single iron labeled cancer cells in mouse brain: Comparison of FIESTA imaging protocols at 1.5 and 3.0 Tesla
Soha Ramadan, B.M.Sc., University of Western Ontario, London, ON, Canada
  Special Session:  Potentials and Pitfalls of Molecular Imaging in Cancer
16:50 Molecular Imaging, Alnawaz Rehemtulla, Ph.D., MSC, University of Michigan, Ann Arbor, MI, USA
17:35 Roundtable Discussion, Michael Garwood, Ph.D., Moderator
18:30 Dinner
Monday, 16 October 2006
07:30 Breakfast
  Oral session 7: Clinical Translation of MRS, Jeffry Alger, Ph.D., Chair
09:00 MR Spectroscopy in Clinical Oncology
Arend Heerschap, Ph.D., Radboud University, Nijmegen, The Netherlands
09:25 MR Spectroscopy of the Breast
Patrick J. Bolan, University of Minnesota, Minneapolis MN, USA
  Proffered Papers
09:50 Arterial spin labeling and magnetic resonance spectroscopy in differentiation of gliomas
Sanjeev Chawla,, M.Sc., University of Pennsylvania, Philadelphia, PA, USA
10:05 Fast non-invasive 3D proton-MR spectroscopic imaging of the human prostate at 3 Tesla without an endorectal coil
Tom Scheenen, Ph.D., Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
10:25 MR determined metabolic phenotype predicts apoptosis in treatment of cervical carcinomas
Tone F. Bathen, Ph.D., NTNU, Trondheim, Norway
10:40 Break
  Oral Session 8: Tumor Models/MRS and Metabolism, Jerry Glickson, Ph.D., Chair
11:00 Alterations of Choline Phospholipid Metabolism in a Model Of Epithelial Ovarian Tumor Progression
Franca Podo, D.Sc., Istituto Superiore di Sanitá, Rome, Italy
11:25 MRS In The Evaluation Of Molecularly Targeted Cancer Therapeutics - not available
Mounia Beloueche-Babari, Ph.D., Royal Marsden Hospital, Sutton, Surrey, England, UK
  Proffered Papers
11:50 siRNA-mediated choline kinase suppression sensitizes breast cancer cells to 5-fluorouracil treatment
Kristine Glunde, Ph.D., Johns Hopkins University, Baltimore, MD, USA
12:05 The PPAR-γ inhibitor GW9662 attenuates phenylbutyrate-induced lipid metabolite accumulation in DU145 prostate cancer cells
Matthew Milkevitch, Ph.D., University of Pennsylvania, Philadelphia, PA, USA
12:20 Phosphocholine levels are modulated downstream of MAPK and PI3K signaling via inhibition of fatty acid synthase
James Ross, Ph.D. M.D., Anderson Cancer Center, Houston, TX, USA
12:35 Closing Remarks
12:45 Box Lunch

The International Society for Magnetic Resonance in Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.